Meta-analysis of BRCA1 and BRCA2 penetrance.

By Sining Chen, Giovanni Parmigiani. Journal of Clinical Oncology, 2007

1,823 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality (2010, positive): “The estimated ovarian cancer risks range from 36% to 63% for BRCA1 mutation carriers and 10% to 27% for BRCA2 mutation carriers.(3-6) Women who are mutation carriers have cancer risk–management options that include risk-reducing salpingooophorectomy, risk-reducing mastectomy, annual cancer screening”
Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk (2011, positive): “While BRCA1 and BRCA2 mutations are highly penetrant [1], resulting in higher risk for breast cancer, both of these genes are also highly polymorphic.”
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers (2017, neutral): “05 14 (9-21) 36 (30-43) 56 (49-63) 64 (57-71)”
Risk Factors and Preventions of Breast Cancer (2017, positive): “A meta-analysis by Chen showed that the breast cancer risk ratio in women older than 70 years carrying BRCA1 or BRCA2 mutations was 57% and 49%, respectively [32].”
Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention (2017, background): “Carriers of a BRCA1mutation have up to a 46% risk of developing ovarian cancer by age 70 (1); in contrast, the general population lifetime risk of ovarian cancer is only 1.”